3b blackbio dx Limited has announced that its Board of Directors will convene on February 6, 2026, to review and approve the company's quarterly financial performance. The meeting represents a key milestone in the company's regulatory compliance and investor communication process.

Board Meeting Details

The board meeting has been scheduled with specific parameters to ensure proper governance and regulatory adherence:

Financial Results Scope

The board will review comprehensive financial statements covering multiple aspects of the company's performance. The meeting agenda includes consideration and approval of both unaudited standalone and consolidated financial results for the specified period. This dual approach provides stakeholders with a complete view of the company's financial position, including subsidiary performance and standalone operations.

Trading Window Restrictions

In compliance with SEBI regulations regarding insider trading, 3B BlackBio Dx Limited has implemented trading window restrictions to maintain market integrity:

Regulatory Compliance

The board meeting announcement fulfills the company's obligations under Regulation 29(1) and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has formally notified BSE Limited through its Department of Corporate Relations, ensuring proper disclosure to market participants and regulatory authorities.

The communication was signed by Nikhil Kuber Dubey, Whole Time Director, demonstrating appropriate corporate governance and executive oversight in the disclosure process.

3B BlackBio DX Limited (formerly Kilpest India Limited) has received a regulatory disclosure from promoter Mahesh Kumar Upadhyay regarding the sale of equity shares under SEBI regulations. The transaction involved the disposal of 400 equity shares through open market operations conducted over two consecutive days in December 2025.

Transaction Details

The share sale was executed in two separate tranches, with 150 equity shares sold on December 23, 2025, and 250 equity shares sold on December 24, 2025. The disclosure was submitted to BSE Limited and the company on December 24, 2025, in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Shareholding Changes

Prior to the transaction, Mahesh Kumar Upadhyay held 24,250 equity shares carrying voting rights in 3B BlackBio DX Limited. Following the sale of 400 shares, his holding reduced to 23,850 equity shares. The percentage shareholding remains at 0.28% of the company's total voting capital both before and after the transaction.

Company Capital Structure

The company's equity share capital structure remained unchanged following the transaction. 3B BlackBio DX Limited maintains its total equity share capital at ₹8.58 crores, comprising 85,82,670 equity shares with a face value of ₹10.00 each. The total diluted share capital also stands at the same level, indicating no outstanding convertible securities or warrants.

Regulatory Compliance

The disclosure demonstrates adherence to SEBI's transparency requirements for substantial shareholding changes. Mahesh Kumar Upadhyay, identified as belonging to the promoter group, fulfilled his regulatory obligations by submitting the required documentation to both BSE Limited and the company's corporate relations department. The disclosure was signed by Whole Time Director Nikhil Kuber Dubey (DIN: 00538049) on behalf of the company.